Business Monitor International


Vietnam Pharmaceuticals & Healthcare Report

Published 26 March 2014

  • 128 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Vietnam Pharmaceuticals & Healthcare Report

BMI View: Vietnam's reliance on imported drugs (both generic and patented) will continue to provide ample commercial opportunities for foreign drugmakers. However, the population's concerns over drug quality means that only companies with relatively positive branding are likely to succeed in the Vietnamese pharmaceutical market. In addition, downside risks for foreign generic drug manufacturers include free trade agreements and the government's aim to promote locally produced drugs.

Headline Expenditure Projections

  • Pharmaceuticals: VND69,297bn (US$3.30bn) in 2013 to VND80,680bn (US$3.92bn) in 2014; +16.4% in local currency terms and +19.1% in US dollar terms.

  • Healthcare: VND230,140bn (US$10.94bn) in 2013 to VND263,931bn (US$12.8bn) in 2014; +14.7 in local currency terms and +17.3% in US dollar terms.

Risk/Reward Rating : Vietnam's Pharmaceutical Risk/Reward Rating (RRR) score for Q214 is 49.1 out of the maximum 100 in our newly improved RRR system. The country scored above average for some indicators and sub-indicators, including overall market expenditure and sector value growth, pensionable population. Consequently, with this moderate score Vietnam continues ranked 11 th behind Thailand out of the 19 key markets in Asia Pacific.

Key Trends And Developments

  • In March 2014, Vietnam's Health Minister Nguyen Thi Kim Tien proposed several changes to improve payment policies and reduce violations in the healthcare sector. The health ministry will propose solutions such as setting up new criteria for starting salaries and adding seniority allowances, Tien stated. Doctors' starting wages need to be higher than those of other agencies due to the training costs involved, Tien added. The ministry will also try to reduce hospital overloads to cut down working hours and pressures on doctors. The service fees will be recalculated as the government only provides insurance to families living in poverty, near-poverty or other special cases, Tien added. The ministry also...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales Indicators, 2010-2018
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Indicators, 2010-2018
19
Table: Healthcare Governmental Indicators, 2010-2018
20
Table: Healthcare Private Indicators, 2010-2018
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Sales Indicators, 2010-2018
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, 2010-2018
25
Generic Drug Market Forecast
26
Table: Generic Drug Sales Indicators, 2010-2018
27
OTC Medicine Market Forecast
28
Table: OTC Medicine Sales Indicators, 2010-2018
30
Pharmaceutical Trade Forecast
31
Table: Vietnam Pharmaceutical Trade Data And Forecasts (US$mn)
32
Table: Vietnam Pharmaceutical Trade Data And Forecasts (VNDmn)
33
Other Healthcare Data
33
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Table: Vietnam - Economic Activity
39
Industry Risk Reward Ratings
40
Asia Risk/Reward Ratings
40
Vietnam Risk/Reward Ratings
46
Rewards
46
Risks
46
Market Overview
48
Industry Trends And Developments
50
Epidemiology
50
Healthcare Financing
52
Hospital Sector
54
Private Healthcare Sector
56
Healthcare Insurance
57
Healthcare And Pharmaceutical Reform
59
Research And Development
61
Biotechnology Sector
63
Clinical Trials
66
Regulatory Development
69
Regulatory Regime
69
Pharmaceutical Advertising
70
Intellectual Property Environment
71
Corruption
74
Pricing Regime
75
Reimbursement Regime
79
Pricing And Reimbursement Developments
81
Competitive Landscape
83
Pharmaceutical Sector
83
Domestic Industry
84
Foreign Industry
87
Traditional Medicines
89
Pharmaceutical Distribution
90
Pharmaceutical Retail Sector
91
Table: Key Aspects Of Good Pharmacy Practice In Developing Countries
92
Company Profile
93
DHG Pharmaceutical
93
Traphaco Pharmaceutical
95
Vietnam Pharmaceutical Corporation (Vinapharm)
97
Vietnam OPV Pharmaceutical Co
100
Vietnam Pharmaceutical Joint Stock Company (Ampharco)
102
Vidipha Central Pharmaceutical Joint Stock Company
105
Pfizer
107
Sanofi
109
Novartis
113
Merck & Co
115
GlaxoSmithKline
117
Demographic Forecast
119
Table: Vietnam's Population By Age Group, 1990-2020 ('000)
120
Table: Vietnam's Population By Age Group, 1990-2020 (% of total)
121
Table: Vietnam's Key Population Ratios, 1990-2020
122
Table: Vietnam's Rural And Urban Population, 1990-2020
122
Glossary
123
Methodology
125
Pharmaceutical Expenditure Forecast Model
125
Healthcare Expenditure Forecast Model
125
Notes On Methodology
126
Risk/Reward Ratings Methodology
127
Ratings Overview
128
Table: Pharmaceutical Risk/Reward Ratings Indicators
128
Indicator Weightings
129

The Vietnam Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Vietnam Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Vietnamese pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Vietnam to test other views - a key input for successful budgeting and strategic business planning in the Vietnamese pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Vietnamese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Vietnam.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc